Abstract
Background: The prediction of disease severity in COVID-19 is valuable for providing appropriate supportive care earlier and reducing mortality. We aimed to evaluate the impact of baseline cortisol values on disease severity and assess the correlation between the neutrophil to lymphocyte ratio (NLR) and cortisol levels.
Methods: In this retrospective study, we compared the prognostic value of baseline the NLR, morning cortisol, ferritin, and C-reactive protein (CRP) levels among patients with severe and nonsevere COVID-19. The relationships were assessed with Spearman’s correlation.
Results: Of 167 patients, 63 (37.7%) had severe disease, and their baseline cortisol levels were higher than those in the nonsevere group (18.92 µg/dL vs 13.8 µg/dL, p=0.011). The baseline cortisol level and NLR had area under the curve (AUC) values of 0.62 (95% confidence interval [CI] 0.53-0.71) and 0.70 (CI 95% 0.62-0.78) for the prediction of severe COVID-19, respectively. Severe disease was predicted in patients with a baseline cortisol cutoff ≥ 18.92 µg/dL (552 nmol/L) with a specificity of 75.0%, a sensitivity of 50.79%. The cutoff value for the NLR on day 1 was ≥ 6.2, with a specificity of 93.27% and a sensitivity of 32.79%. Baseline cortisol levels showed a significant weak-moderate positive correlation with the NLR and levels of CRP and ferritin on day 1 (r=0.33, r= 0.29, r= 0.28, respectively, p<0.001 for all).
Conclusions: The baseline cortisol level in COVID-19 patients is a good predictive marker for disease severity and non-inferior to the NLR. However, it is inferior to CRP and ferritin.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.